# Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

> **NCT02858271** · PHASE1 · COMPLETED · sponsor: **Aerpio Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AKB-9778 subcutaneous injection

## Key facts

- **NCT ID:** NCT02858271
- **Lead sponsor:** Aerpio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858271, "Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02858271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*